Mircera Review Provided FDA With Forum To Suggest Ideal ESA Studies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With FDA’s review of Roche’s Mircera BLA, the agency went beyond the normal evaluation leading to approval of the drug; it seized the opportunity to weigh in on the proper development of erythropoiesis-stimulating agents.